ProfoundBio: $112 Million Closed To Develop Novel Antibody-Drug Conjugate Therapeutics for Patients With Cancer
By Amit Chowdhry ● Feb 14, 2024
ProfoundBio - a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer - announced an oversubscribed $112 million Series B financing supported by a syndicate of top healthcare dedicated and mutual fund institutional investors. The funding round was led by Ally Bridge Group, with substantial contributions from new investors including Nextech Invest, funds and accounts advised by T. Rowe Price Associates, Janus Henderson Investors, RA Capital Management, OrbiMed, Surveyor Capital (a Citadel company), Medicxi, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital and LifeSci Venture Partners, as well as continued support from existing investors Lilly Asia Ventures (LAV) and LYFE Capital.